New Agents and Strategies in CLL Treatment

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Chronic Lymphocytic Leukemia (CLL) is a hematologic malignancy.
• Fludarabine Monophosphate (FLU) is an adenosine analogue with known anti-leukemic properties.

Purpose of the Study:

• To evaluate the efficacy and toxicity of Fludarabine Monophosphate (FLU) alone and in combination with prednisone (P) for Chronic Lymphocytic Leukemia (CLL).
• To assess the impact of prednisone addition on response rates, survival, and toxicity in CLL patients.

Main Methods:

• Retrospective analysis of previously treated and untreated CLL patients receiving FLU or FLU + P.
• Response rates (CR, nodular CR, PR), median survival, and toxicity (febrile episodes, thrombocytopenia) were assessed.
• Flow-cytometry and immunoglobulin gene rearrangement studies were used to detect residual disease.

Main Results:

• FLU alone and FLU + P showed similar overall response rates (58% vs 52% in previously treated; 83% vs 82% in previously untreated).
• Median survival was comparable (74 weeks for FLU vs 103 weeks for FLU + P in previously treated).
• No significant advantage was observed with the addition of prednisone; persistent thrombocytopenia was noted in some FLU + P patients.

Conclusions:

• Fludarabine Monophosphate (FLU) demonstrates significant anti-leukemic activity in CLL.
• Addition of prednisone to FLU does not appear to enhance response rates or survival and may increase toxicity.
• Further studies are exploring combination therapies and post-remission strategies like autologous bone marrow transplantation.